CompletedNot Applicable

Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

France21 participantsStarted 2010-12

Plain-language summary

This study is conducted in Europe. The aim of this prospective, observational study are to describe the different clinical practice and detailed haemostatic management of activated recombinant human factor VII (NovoSeven®) in patients with acquired haemophilia in France. The secondary aim is to assess the primary haemostasis disorder associated with the coagulation disorders, if available.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed with acquired haemophilia * Treated with activated recombinant human factor VII as first line treatment * Treated with activated recombinant human factor VII after January 2011 Exclusion Criteria: * Patients with first diagnosis before january 2010 and having a relapse after january 2011 * Known hypersensitivity to NovoSeven®, or to mouse, hamster or bovine protein

What they're measuring

Identification of decision criteria to treat patient with activated recombinant human factor VII

Timeframe: Year 3

Trial details

NCT IDNCT01285089

SponsorNovo Nordisk A/S

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2013-10

View on ClinicalTrials.gov More Acquired Bleeding Disorder trials